BMI Diabetes Preserved Ejection Fraction 
American College of Cardiology
NOVEMBER 18, 2024
What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased. Overall, 60.9%
European Journal of Heart Failure
NOVEMBER 19, 2024
BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; HELLP, haemolysis, elevated liver enzymes, low platelet count. Shortly after delivery, women who experienced HDP express increased risk of classic CV risk factors such as hypertension, renal disease, abnormal lipid profile, and diabetes.
Cardiometabolic Health Congress
JULY 25, 2023
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] These individuals tend to have a better prognosis when compared to both individuals with normal weight (BMI of 18.5
DAIC
JUNE 26, 2024
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. It also lowered their systolic blood pressure and waist circumference.
Expert insights. Personalized for you.
64 
Let's personalize your content